Press Release

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com
www.corcept.com

Corcept Therapeutics to present at Thomas Weisel Partners Healthcare Conference on September 7, 2006

MENLO PARK (August 30, 2006) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) today announced that the company will present at the Thomas Weisel Partners Healthcare Conference on Thursday, September 7th at 10:20 a.m. (EDT) at the Four Seasons Hotel in Boston. The presentation will cover the company's clinical and corporate progress.
A live and subsequent archive of the Corcept presentation will be available on September 7, 2006 via webcast at: http://www.veracast.com/webcasts/twp/healthcare06/36205424.cfm
The webcast will be available for 2 weeks.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX®, is currently in Phase III clinical trials for the treatment of the psychotic features of psychotic major depression (PMD). The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD.
For additional information about the company, please visit www.corcept.com.